Oxford, UK-headquartered advisory firm PharmaVentures has appointed Aki von Roy as an associate based in Auckland, New Zealand.
He has over 30 years experience in pharma and 16 years in biotech, and has been involved in 18 start up or merger ventures as director or investor.
Von Roy said: “I am delighted to join PharmaVentures, a firm with a proven track record in deal making.”
Formally he was the European president of Bristol-Myers Squibb (BMS), where he was responsible for $2.2bn in sales, more than 7,500 employees and around 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters.
Von Roy has also been chairman of private and publicly traded companies such as Genesis R&D, Phylogica, Vital Foods and Phytomedics and currently works as a venture partner at BioPacificVentures and an advisor to Direct Capital.
Fintan Walton, CEO of PharmaVentures, added: “Aki has a unique insight into innovative healthcare in the Asia-Pacific region and he will be a great benefit to both PharmaVentures and its clients.”